28th PAGE Meeting

Stockholm - Sweden
11-14 June, 2019

View abstracts

Home / 2019 – Stockholm – Sweden / Abstracts

← Back to filters

Abstracts (17)

I-08Bambang Adiwijaya

Component score models of HAMD were more predictive than total score models

Wednesday 09:50-11:15

I-19Muhammad Waqar Ashraf

Mechanistic model to characterize the pharmacokinetics and -dynamics of subcutaneous dexmedetomidine in healthy adult volunteers

Wednesday 09:50-11:15

I-45Irina Bondareva

Population pharmacokinetics of levetiracetam (LEV) in preterm neonates with seizures based on sparse therapeutic drug monitoring (TDM) data

Wednesday 09:50-11:15

I-48Agnieszka Borsuk-De Moor

The influence of age and body weight on pharmacokinetics and pharmacodynamics of dexmedetomidine in rabbits

Wednesday 09:50-11:15

I-61Fernando Carreño

Population Pharmacokinetic Modeling of Quetiapine Lipid Core Nanocapsules in a Neurodevelopmental Animal Model of Schizophrenia

Wednesday 09:50-11:15

I-65Anne Chain

A Model Based Meta-Analysis of second generation antipsychotics for the treatment of Schizophrenia

Wednesday 09:50-11:15

I-81Kim Dao

Pharmacokinetic Profile of Sultiame in Healthy Volunteers with In Vitro Characterization of Its Uptake by Red Blood Cells

Wednesday 09:50-11:15

II-38Nicolás Marco Ariño

Pharmacodynamic modelling of pupil diameter after noxious stimulus in patients undergoing surgery

Wednesday 15:10-16:40

II-42Mark Meerson

Quantitative systems pharmacology model of key intraneuronal pathways regulating toxic protein accumulation in Alzheimer’s disease

Wednesday 15:10-16:40

II-50Jonathan Mochel

A Physiologically-Based Pharmacokinetic (PBPK) Model for the Prediction of Levodopa (L-dopa) Disposition in Plasma and Various Brain Compartments Across Species

Wednesday 15:10-16:40

II-64Andrés Olivares-Morales

Bayesian pharmacokinetic (PK) and pharmacodynamic (PD) modelling of the qEEG response to a selective GABAA a5 receptor modulator in rats to inform its use as a translational biomarker

Wednesday 15:10-16:40

III-12Marina Savelieva

Modeling decline in cognition to decline in function in Alzheimer’s disease

Thursday 09:55-11:20

III-89Xuan Zhou

Model-Based Estimation of Probability of Pharmacological Success for CNS Compounds

Thursday 09:55-11:20

IV-48Thomas Henthorn

A population pharmacokinetic model of dense delta-9-tetrahydrocannabinol (THC), 11-OH-THC, and THCCOOH data and its use to estimate daily exposure in an observational cannabis study with sparse data

Thursday 15:25-16:50

IV-55Ziad Hussein

Population Pharmacokinetics of Lemborexant, a Dual Orexin Receptor Antagonist, in Healthy Adult and Elderly Subjects and Subjects with Primary Insomnia

Thursday 15:25-16:50

IV-74Tatiana Karelina

Amyloid β in vitro prion properties and in vivo pathology exacerbation mechanisms studied by translation quantitative systems pharmacology model for prediction of anti-protofibril immunotherapy effects

Thursday 15:25-16:50

IV-83Seoyoung Kim

Population Pharmacokinetic-Pharmacodynamic Modeling of Escitalopram in Patients with Obsessive-Compulsive Disorder Using Yale-Brown Obsessive Compulsive Scale

Thursday 15:25-16:50